Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses

Summary

Loss of p53 function contributes to the development of many cancers. While cell-autonomous consequences of p53 mutation have been studied extensively, the role of p53 in regulating the anti-tumor immune response is still poorly understood. Here, we show that loss of p53 in cancer cells modulates the tumor-immune landscape to circumvent immune destruction. Deletion of p53 promotes the recruitment and instruction of suppressive myeloid CD11b ⁺ cells, in part through increased expression of CXCR3/CCR2-associated chemokines and macrophage colony-stimulating factor (M-CSF), and attenuates the CD4 ⁺ T helper 1 (Th1) and CD8 ⁺ T cell responses in vivo. p53-null tumors also show an accumulation of suppressive regulatory T (Treg) cells. Finally, we show that two key drivers of tumorigenesis, activation of KRAS and deletion of p53, cooperate to promote immune tolerance.

Graphical Abstract

Highlights

• •

  Tumor-specific loss of p53 delays tumor rejection in immune-competent hosts

• •

  p53 loss increases myeloid infiltration through enhanced cytokine secretion

• •

  The increase in Treg cells in response to loss of p53 is independent of Kras mutation

• •

  Kras mutations coordinate with p53 loss to regulate myeloid recruitment

Abstract

TP53 is one of the most frequently mutated genes in cancer; however, its significance in controlling tumor-immune crosstalk is not fully understood. Blagih et al. highlight a key role for tumor-associated loss of p53, a common oncogenic event, in regulating myeloid and T cell responses.